Wilson Sonsini advised VitroLabs on the deal. VitroLabs Inc, a Bay-Area-based biotech company leading the development of a new scientific process to grow the world’s first […]
VitroLabs’ $46 Million Series A Financing
Cellino’s $80 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing […]
Iterative Scopes’ $150 Million Series B Funding
Wilson Sonsini Goodrich & Rosati advised Iterative Scopes on the deal. Iterative Scopes, a pioneer in the development of precision-based gastrointestinal (GI) disease technologies and software, […]
Lycia Therapeutics’ $70 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal while Fenwick & West represented Lycia Therapeutics. Lycia Therapeutics, Inc., a leader in extracellular protein […]
Vigil Neuroscience’s $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of […]
Iterative Scopes’ $30 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Iterative Scopes on the deal. Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, closed a […]
AbSci’s Acquisition of Totient
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition […]